Evidence map›Paper›PMID 40092130›Full record

ArticleAmerican journal of translational research2025

RBM10 suppresses malignant transformation in endometrial cancer via the Hippo-YAP signaling pathway.

Wei Shi, Mengfei Wang, Qin Lin, Zeheng Lv, Kun Gao, Xiaoping Wan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei ShiShanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai 200092, China.
Mengfei WangShanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai 200092, China.
Qin LinShanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai 200092, China.
Zeheng LvShanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai 200092, China.
Kun GaoDepartment of Clinical Laboratory, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai 200092, China.
Xiaoping WanShanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai 200092, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the genetic alterations, pathobiological functions, and downstream molecular mediators of RBM10 in endometrial cancer (EC) cells.

methodsTargeted sequencing and The Cancer Genome Atlas (TCGA) dataset analysis were performed. Following knockout (KO) or exogenous overexpression of RBM10 in EC cell lines, the biological functions and underlying mechanism of RBM10 in EC cells were evaluated by Western blot, qRT-PCR, CCK-8, Transwell, RNA-sequencing (RNA-seq), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.

resultsRBM10 mutation was present in a subset of ECs. RBM10 KO EC cells showed increased growth, migration, and invasion, compared to parental cells. Conversely, RBM10 overexpression reduced EC cell growth, migration, and invasion. KEGG pathway enrichment analysis showed that the expression of the Hippo-YAP pathway downstream targets was markedly upregulated in RBM10 KO EC cells. Mechanistically, RBM10 suppressed Yes Kinase-associated Protein (YAP) activity by promoting YAP phosphorylation.

conclusionRBM10 acts as tumor suppressor in EC by modulating the Hippo-YAP signaling pathway.

Indexed as

Endometrial cancergrowthHippo-YAP signaling pathwayinvasionmigrationRNA-binding motif protein 10

Identifiers

PMID40092130
PMCPMC11909570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.